Veracyte (VCYT)
(Delayed Data from NSDQ)
$32.84 USD
-0.13 (-0.39%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $32.96 +0.12 (0.37%) 7:58 PM ET
1-Strong Buy of 5 1
F Value A Growth A Momentum B VGM
Balance Sheet
Fiscal Year End for Veracyte, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 216 | 179 | 173 | 349 | 159 |
Receivables | 40 | 44 | 41 | 18 | 19 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 16 | 14 | 11 | 5 | 7 |
Other Current Assets | 13 | 11 | 17 | 3 | 2 |
Total Current Assets | 286 | 249 | 243 | 376 | 188 |
Net Property & Equipment | 21 | 18 | 15 | 9 | 9 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 792 | 871 | 911 | 63 | 68 |
Deposits & Other Assets | 7 | 6 | 3 | 2 | 2 |
Total Assets | 1,115 | 1,156 | 1,188 | 457 | 275 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 13 | 12 | 12 | 3 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 1 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 38 | 38 | 39 | 12 | 14 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 5 | 9 | 8 | 0 | 0 |
Total Current Liabilities | 61 | 63 | 64 | 17 | 17 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 5 | 6 | 1 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 1 | 1 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 3 | 7 | 8 | 6 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 71 | 81 | 91 | 36 | 36 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,536 | 1,500 | 1,469 | 703 | 486 |
Retained Earnings | -468 | -394 | -357 | -282 | -247 |
Other Equity | -24 | -31 | -15 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 1,044 | 1,075 | 1,097 | 421 | 239 |
Total Liabilities & Shareholder's Equity | 1,115 | 1,156 | 1,188 | 457 | 275 |
Total Common Equity | 1,044 | 1,075 | 1,097 | 421 | 239 |
Shares Outstanding | 73.00 | 71.70 | 71.00 | 57.90 | 48.80 |
Book Value Per Share | 14.30 | 15.00 | 15.44 | 7.28 | 4.91 |
Fiscal Year End for Veracyte, Inc falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 236 | 209 | 216 | 202 | 191 |
Receivables | 50 | 47 | 40 | 39 | 42 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 19 | 18 | 16 | 16 | 12 |
Other Current Assets | 16 | 16 | 13 | 14 | 14 |
Total Current Assets | 321 | 290 | 286 | 271 | 259 |
Net Property & Equipment | 22 | 22 | 21 | 19 | 19 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 865 | 870 | 792 | 817 | 864 |
Deposits & Other Assets | 8 | 7 | 7 | 6 | 7 |
Total Assets | 1,234 | 1,200 | 1,115 | 1,125 | 1,161 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 12 | 12 | 13 | 13 | 13 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 43 | 30 | 38 | 35 | 34 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 10 | 10 | 5 | 5 | 6 |
Total Current Liabilities | 72 | 58 | 61 | 57 | 58 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 1 | 1 | 4 | 5 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 14 | 1 | 1 | 6 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 102 | 81 | 71 | 71 | 78 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,627 | 1,617 | 1,536 | 1,528 | 1,521 |
Retained Earnings | -464 | -470 | -468 | -34 | -410 |
Other Equity | -31 | -29 | -24 | -440 | -28 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 1,133 | 1,119 | 1,044 | 1,054 | 1,083 |
Total Liabilities & Shareholder's Equity | 1,234 | 1,200 | 1,115 | 1,125 | 1,161 |
Total Common Equity | 1,133 | 1,119 | 1,044 | 1,054 | 1,083 |
Shares Outstanding | 76.40 | 76.40 | 73.00 | 72.70 | 72.40 |
Book Value Per Share | 14.82 | 14.64 | 14.30 | 14.50 | 14.95 |